Synthesis Platform
Supporting PepMetics® Drug Discovery
Drug discovery with PepMetics® compounds requires a synthesis platform capable of efficiently producing diverse molecular structures. Through the synthesis of the PepMetics® Library, PRISM BioLab has established extensive proprietary know-how, enabling rapid compound synthesis and agile drug discovery efforts.
Structural Diversity
Through Scaffold–Fragment Combinations
PepMetics® compounds are constructed by assembling molecular fragments. Two key intermediates are prepared from fragments, from which compounds with unique scaffolds can be synthesized efficiently. A diverse set of intermediates allows rapid combinatorial synthesis, enabling efficient generation of compounds.
Over 20 years of synthesis experience has been fully documented in electronic laboratory notebooks, including both successful and unsuccessful examples, ensuring continuous accumulation and use of knowledge.
Automation
PepMetics® compounds are well suited to solid-phase synthesis, similar to peptide synthesis, enabling efficient automation. By applying solid-phase synthesis, parallel synthesis of large numbers of compounds becomes possible. This capability supports both expansion of the PepMetics® Library and rapid optimization of hit compounds.
PRISM BioLab is also advancing automation across purification and sample preparation processes, further accelerating the drug discovery workflow.
Syro I
Automated Parallel Synthesis Workstation
Courtesy of Biotage Japan Ltd.
PepMetics® compounds are amenable to combinatorial synthesis through combinations of scaffolds and multiple side-chain fragments. By building manufacturing processes focused on synthesis efficiency, PRISM BioLab synthesizes and evaluates diverse compounds with the ultimate goal of generating superior clinical candidate compounds.
